trial

Hormonal and Inflammatory Biomarkers and Response to Cognitive Remediation in Recent-onset Psychosis

NCTId NCT04418570
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 28 (actual)
Sponsored by Corporacion Parc Tauli
Primary completion 2020-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
28 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Single
Start
2016-07
Primary completion
2020-03
Eligibility
ALL · 18 Years · 40 Years

Interventions & indications

Drugs
Cognitive Remediationattendance to an Early Intervention Service for Psychosis

Sponsors

Corporacion Parc TauliLead Sponsor
Instituto de Salud Carlos IIICollaborator

Investigators

1
Javier Labad, M.D., Ph.D.Principal Investigator

Sites

0 total

Facts & assertions

4 sourced
Enrollment
28
Phase
NA
Primary Completion Date
2020-03
Status
COMPLETED
relationships
The graph out of here
drug
Cognitive Remediation
drug
attendance to an Early Intervention Service for Psychosis
drug
lead_sponsor
Corporacion Parc Tauli
company
collaborator
Instituto de Salud Carlos III
company
indication
Inflammation
indication
Psychotic Disorders
indication
Thyroid Diseases
indication
investigator
Javier Labad, M.D., Ph.D.
person